{"id":40282,"date":"2017-09-08T07:09:25","date_gmt":"2017-09-08T11:09:25","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40282"},"modified":"2017-09-08T07:09:25","modified_gmt":"2017-09-08T11:09:25","slug":"immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282","title":{"rendered":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc &#8211; Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>ImmunoGen, Inc. (NASDAQ:IMGN)<\/strong> announced recently that they are entering into a partnership and option agreement with Jazz Pharmaceuticals plc \u2013Ordinary Shares (NASDAQ:JAZZ) to develop and commercialize the stage two, hematology-related Antibody-Drug Conjugate (ADC) programs in addition to another program that will be authorized within the terms of agreement.<\/p>\n<p style=\"text-align: justify;\">The programs will cover the IMGN779- CD33-targeting ADC which is still in phase I of the study and will be used to treat acute myeloid leukemia (AML) and the IMGN632 that is still under investigations in the preclinical study for curing hematological malignancies such as the AML. The IMGN632 is expected to enter into clinical stage before the end of the year.<\/p>\n<p style=\"text-align: justify;\">Under the terms of the new agreement, the Jazz Pharmaceuticals will be granted the exclusive and worldwide rights to develop and supply the ADC program as well as the other single program that will be launched during the period of collaboration. Similarly, ImmunoGen will manage the development of three ADC programs before Jazz opts-in in which the company will leave the responsibility to Jazz for further development including the possible regulatory compliances and commercialization.<\/p>\n<p style=\"text-align: justify;\">The agreement also stipulates that Jazz will give ImmunoGen an upfront compensation of $75 million. Furthermore, Jazz will pay over $100 million funds to ImmunoGen for over seven years in the support of the three ADC programs. For each program that Jazz would opt-in, the ImmunoGen would be entitled to a sum of milestone payments in accordance with the regulatory approvals of the products and much more.<\/p>\n<p style=\"text-align: justify;\">After Jazz has opted-in, the two companies will then share the costs related to the development and attainment of the regulatory approvals of the applicable products supplied both in the US and European Union countries. Currently, ImmunoGen has some rights to co-commercialize one or two products subject to certain circumstances.<\/p>\n<p style=\"text-align: justify;\">The collaboration will support the two companies\u2019 long-term commitment to advance in the hematology or oncology portfolios with the possibility of adding advanced ADCs in the future. The new programs will help develop therapeutic options that are urgently needed for cancer patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmunoGen, Inc. (NASDAQ:IMGN) announced recently that they are entering into a partnership and option agreement with Jazz Pharmaceuticals plc \u2013Ordinary Shares (NASDAQ:JAZZ) to develop and [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":40292,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12851,12659,1764,12853,12852,358,1765,6918],"stock_ticker":[],"class_list":["post-40282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-imgn","tag-immunogen-inc","tag-immunogen-inc-nasdaqimgn","tag-jazz-pharmaceuticals-plc","tag-jazz-pharmaceuticals-plc-nasdaqjazz","tag-nasdaq","tag-nasdaqimgn","tag-nasdaqjazz","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"ImmunoGen, Inc. (NASDAQ:IMGN) announced recently that they are entering into a partnership and option agreement with Jazz Pharmaceuticals plc \u2013Ordinary Shares (NASDAQ:JAZZ) to develop and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-08T11:09:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"554\" \/>\n\t<meta property=\"og:image:height\" content=\"317\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc &#8211; Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule\",\"datePublished\":\"2017-09-08T11:09:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg\",\"keywords\":[\"IMGN\",\"ImmunoGen Inc\",\"ImmunoGen Inc (NASDAQ:IMGN)\",\"Jazz Pharmaceuticals plc\",\"Jazz Pharmaceuticals plc (NASDAQ:JAZZ)\",\"NASDAQ\",\"NASDAQ:IMGN\",\"NASDAQ:JAZZ\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\",\"name\":\"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg\",\"datePublished\":\"2017-09-08T11:09:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg\",\"width\":554,\"height\":317},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc &#8211; Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282","og_locale":"en_US","og_type":"article","og_title":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR","og_description":"ImmunoGen, Inc. (NASDAQ:IMGN) announced recently that they are entering into a partnership and option agreement with Jazz Pharmaceuticals plc \u2013Ordinary Shares (NASDAQ:JAZZ) to develop and [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-09-08T11:09:25+00:00","og_image":[{"width":554,"height":317,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc &#8211; Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule","datePublished":"2017-09-08T11:09:25+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg","keywords":["IMGN","ImmunoGen Inc","ImmunoGen Inc (NASDAQ:IMGN)","Jazz Pharmaceuticals plc","Jazz Pharmaceuticals plc (NASDAQ:JAZZ)","NASDAQ","NASDAQ:IMGN","NASDAQ:JAZZ"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282","url":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282","name":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg","datePublished":"2017-09-08T11:09:25+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40291-s-4be5c137ff55dfd2e5775db6c11ed119410f321c.jpg","width":554,"height":317},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/immunogen-inc-nasdaqimgn-and-jazz-pharmaceuticals-plc-ordinary-shares-nasdaqjazz-collaborates-to-build-adc-molecule-40282#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"ImmunoGen, Inc. (NASDAQ:IMGN) and Jazz Pharmaceuticals plc &#8211; Ordinary Shares (NASDAQ:JAZZ) Collaborates To Build ADC Molecule"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40282"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40282\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40292"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40282"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}